When a feature like the Python extension's environment activation is triggered, the activation command (e.g., conda activate my_env) is now sent directly as input to the REPL process (e.g., R, Julia) ...

Since it is about REPL mode, it may not be so important. Summary There is an issue where source code from the clipboard doesn't paste properly into the REPL shell.

We just received data on a new analyst forecast for $REPL. Robert Driscoll from Wedbush set a price target of 4.0 for REPL.

Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users ...

Fintel reports that on July 22, 2025, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 725.97% Upside As of July 17 ...

Fintel reports that on July 22, 2025, Leerink Partners downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Market Perform. Analyst Price Forecast Suggests 725.97% ...

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Meet the Shell Shock roster for TBT 2025, Maryland’s alumni team stacked with former Terrapin stars and pro veterans. Explore player positions, college ties, and pro background.

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

NEW YORK, NY / ACCESS Newswire / July 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Replimune Group, Inc. ("Replimune Group, Inc.") (NASDAQ:REPL) concerning ...